GSK

GSK

Market cap $102B

GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

GSK's growth is increasingly specialty-led (HIV, RI&I, oncology), not just vaccines. ViiV's long-acting injectables also tap into durable demand. Recent launches/approvals like Blenrep in r/r myeloma and depemokimab in severe asthma should extend GSK's specialty momentum. Additionally, GSK's late-stage pipeline includes 15 candidates targeting large TAMs. I like how Phase 3 CHB data is framed as a potential functional cure opportunity.

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (“GSK”, LSE/NYSE: GSK) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with risvutatug rezetecan (also known as GSK'227), GSK's novel investigational B7-H3 targeting antibody drug conjugate (ADC), across multiple solid tumor settings, including small cell lung cancer (SCLC). “We believe exploring new mec.

AnaptysBio said on Thursday it filed a partial motion to dismiss a claim by GSK's oncology unit, which alleges the biotech breached their contract, escalating a legal dispute over royalties tied to sales of the cancer drug Jemperli.

GSK's bepirovirsen hit primary endpoints in two phase III trials, boosting hopes for a functional cure in chronic hepatitis B patients.

SAN FRANCISCO--(BUSINESS WIRE)-- #GSK--GSK licenses Noetik's AI foundation models in anchor partnership to transform cancer therapeutic research and development.

Ionis Pharmaceuticals Inc. (NASDAQ: IONS) partner GSK Plc (NYSE: GSK) on Wednesday shared data from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, of bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B (CHB). The studies included over 1,800 patients.

GSK PLC (LSE:GSK, NYSE:GSK) said on Wednesday that a potential new treatment for chronic hepatitis B had delivered positive late-stage trial results, raising the prospect of a shorter, more effective therapy for a disease that affects more than 250 million people worldwide. The drug, bepirovirsen, met its primary goal in two large phase III trials, B-Well 1 and B-Well 2, with GSK saying it achieved a “statistically significant and clinically meaningful” functional cure rate when added to existing treatment.

GSK's experimental drug to treat chronic hepatitis B infection met the main goals in two closely watched studies, the drugmaker said on Wednesday, bringing the company a step closer to making a functional cure available to patients.